Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
NCT05036434Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2021
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in adrenocortical carcinoma (ACC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Nov 2021; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT05036434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036434.